Biocept (NASDAQ: BIOC) announced the launch of its EGFR mutation detection testing utilizing a patient's blood-based liquid biopsy. This innovative ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE